U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503587) titled 'Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis' on March 25.
Brief Summary: This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Study Start Date: April 05
Study Type: INTERVENTIONAL
Condition:
Progressive Pulmonary Fibrosis
Intervention:
DRUG: HSK44459
HSK44459 taken orally twice daily in the morning and in the evening for 52weeks.
DRUG: Placebo
Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 52 weeks
Recruitment Status: NO...